
The Roundtable advocates for its priorities in many ways — letters to Congressional and Administration leaders, testimony, press statements, and in meetings with Federal decision-makers.
News & Events
Roundtable Supports IDR Overhaul
The Roundtable has shared a letter supporting House Energy and Commerce Committee Ranking Member Pallone’s Lower Premiums, Faster Payments Act (H.R. 10788). The legislation would replace the No Surprises Act’s (NSA’s) broken arbitration process with a predictable, market-based payment standard. It would also require that providers be paid within 30 days. These changes would protect public sector plan enrollees from premium increases caused by abuse of the independent dispute resolution (IDR) process.
Roundtable Submits Response to Senate Finance Committee RFI on Health Coverage Affordability
On October 2, the Roundtable submitted a response to Senate Finance Committee Ranking Member Ron Wyden’s request for information (RFI), Health Coverage That Works for Everyone. Drawing on data from the Roundtable’s 2025 Specialty Drug Survey and a recent member survey, the letter highlighted the cost pressures facing public sector plans and flagged concerns about rising costs tied to the No Surprises Act’s (NSA’s) arbitration process, consolidation, and potential coverage losses under H.R. 1.
Roundtable Sends Letter to Congressional Leadership Citing NSA Abuses, Costs
On September 21, the Roundtable sent a letter to Congress urging legislative action to curb abuse of the No Surprises Act’s independent dispute resolution (IDR) process, which is inflating out-of-network payments and driving up costs for public sector plan sponsors, employers, and consumers. The letter reaffirms the Roundtable’s support for the NSA itself — which has prevented an estimated 50 million surprise bills since taking effect in 2022 — while documenting how far the arbitration system has drifted from Congressional intent:
Roundtable Signs On to Two Letters to Congressional Leadership
The Roundtable recently signed on to two letters addressing hospital pricing and billing practices. The first letter, coordinated by Families USA, calls on Congressional leadership to close loopholes in the No Surprises Act that are driving up health costs. The letter drew support from 67 organizations spanning consumer groups, labor groups, employer organizations, and patient advocates.
The second letter urged the Trump administration to finalize a “site neutral” payment reform in its proposed Hospital Outpatient Prospective Payment System (OPPS) rule, which would require imaging services without contrast to be priced the same regardless of care setting.
Roundtable Launches 2026 Specialty Drug Survey
The Roundtable and National Institute for Public Employee Health Care Policy administer the Annual Specialty Drug Survey to build a national picture of public employee health care plans and the benefits they offer. Your responses help capture the reach of public sector purchasers, highlight what makes them distinctive, and identify shared challenges in plan design and administration.
The Roundtable Responds to Senate Finance Committee RFI on Policy Options to Lower Drug Prices
On June 16, 2026, the Senate Finance Committee minority staff announced a Request for Information (RFI) titled “Commonsense Policy Options to Lower Drug Prices.” The RFI comes after Ranking Member Wyden (D-OR), along with Senators Cortez Masto (D-NV), Welch (D-VT), and Gallego (D-AZ), released a Dear Colleague letter to the Senate Democratic caucus on February 3, 2026. That letter outlined a three-pronged plan to build on the Inflation Reduction Act and further lower prescription drug prices. Several other Democratic senators, including Kelly (D-AZ), Baldwin (D-WI), Hassan (D-NH), Merkley (D-OR), Van Hollen (D-MD), Duckworth (D-IL), and Blumenthal (D-CT), have since joined the effort.
Roundtable-Supported Drug Pricing Legislation Passes Senate
On July 23, the Senate unanimously voted to pass the Affordable Prescriptions for Patients Act (S. 1041). The bill aims to address “patent thickets,” a strategy that pharmaceutical companies use to overlap patents on a single drug, which blocks competition and keeps drug prices high. This bill,…
Roundtable Signs on to No Surprises Act Independent Dispute Resolution Entity Conflict of Interest Letter to the Administration
The Public Sector HealthCare Roundtable and 47 organizations representing patients, consumers, unions, and employers sent a letter to the Department of Treasury, Department of Health and Human Services (HHS), and Department of Labor urging the Administration to address tactics exploiting the No Surprises Act (NSA) Independent Dispute Resolution (IDR) process. The letter discusses the influence of private equity firms and IDR entities’ conflicts of interest in the growing inflationary story of IDR arbitration cases and payments.
Specialty Drug Costs Continue to Drive Health Care Spending for Public Sector Employers
The National Institute for Public Employee Health Care Policy and the Public Sector HealthCare Roundtable released the 2025 Annual Specialty Drug Survey Report providing analysis of 2024 plan year data from public sector health plans across the country.
The survey includes responses from 23 public sector plan sponsors representing 17 states. Collectively, respondents cover more than 5.5 million beneficiaries and report nearly $30 billion in commercial health care spending, including almost $8 billion in pharmacy benefit spending.
Roundtable Submits Testimony to House Energy and Commerce Subcommittee on Health on Affordability
The Public Sector HealthCare Roundtable submitted testimony to the House Energy and Commerce Subcommittee on Health’s hearing on Lowering Health Care Costs for All Americans: an Examination of the U.S. Provider Landscape. The Roundtable expressed its support for initiatives that constrain health care cost growth and improve affordability for public sector purchasers, beneficiaries, and taxpayers. The Roundtable called for the Committee to address provider consolidation and price opacity to reduce the cost of provider services.
The survey includes responses from 23 public sector plan sponsors representing 17 states. Collectively, respondents cover more than 5.5 million beneficiaries and report nearly $30 billion in commercial health care spending, including almost $8 billion in pharmacy benefit spending.
